GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view
(Reuters) – Consumer healthcare group Haleon expects 2023 organic revenue growth towards the upper end of its 4%-6% forecast, it said on Thursday, on strong demand and the restocking of its respiratory health products due to a bad cold and flu season.
The company, the world’s biggest standalone consumer health business that sells non-prescription drugs, vitamins and oral care products, kept the rest of its full-year 2023 outlook unchanged.
Haleon was carved out of British drugmaker GSK in July last year.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman)
Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.